|
|
|
|
|
|
|
|
|
|
||||||
|
|
Consumer Health |
|||||||||||||
|
€ million |
Q3 – 2013 reported |
Product group transfer adjustments |
Disclosure change1 |
Q3 – 2013 adjusted |
Jan.–Sept. 2013 reported |
Product group transfer adjustments |
Disclosure change1 |
Jan.–Sept. 2013 adjusted |
||||||
|
||||||||||||||
|
Sales |
131.0 |
70.2 |
– |
201.2 |
362.7 |
199.1 |
– |
561.8 |
||||||
|
Royalty, license and |
0.5 |
– |
– |
0.5 |
1.8 |
– |
– |
1.8 |
||||||
|
Total revenues |
131.4 |
70.2 |
– |
201.7 |
364.5 |
199.1 |
– |
563.6 |
||||||
|
|
|
|
|
|
|
|
|
|
||||||
|
Cost of sales1 |
–43.8 |
–16.8 |
– |
–60.6 |
–119.5 |
–60.4 |
– |
–179.9 |
||||||
|
(of which: amortization of intangible assets)1 |
(–) |
(–) |
(–) |
(–) |
(–) |
(–) |
(–) |
(–) |
||||||
|
Gross profit |
87.6 |
53.5 |
– |
141.1 |
245.0 |
138.7 |
– |
383.7 |
||||||
|
Marketing and selling expenses1 |
–54.9 |
–16.6 |
–0.6 |
–72.1 |
–159.3 |
–53.7 |
–1.7 |
–214.7 |
||||||
|
(of which: amortization of intangible assets)1 |
(–) |
(–) |
(–0.6) |
(–0.6) |
(–) |
(–) |
(–1.7) |
(–1.7) |
||||||
|
Royalty, license and |
–0.5 |
–0.1 |
– |
–0.6 |
–1.3 |
–0.3 |
– |
–1.7 |
||||||
|
Administration expenses |
–4.2 |
–1.7 |
– |
–6.0 |
–12.9 |
–5.2 |
– |
–18.1 |
||||||
|
Other operating expenses and income |
–2.3 |
0.6 |
– |
–1.7 |
–6.5 |
0.6 |
– |
–5.9 |
||||||
|
Research and development costs |
–3.9 |
–1.7 |
– |
–5.7 |
–12.3 |
–5.0 |
– |
–17.3 |
||||||
|
|
|
|
|
|
|
|
|
|
||||||
|
Operating result (EBIT) |
21.1 |
34.0 |
– |
55.1 |
51.0 |
75.1 |
– |
126.1 |
||||||
|
Depreciation and amortization |
1.9 |
– |
– |
1.9 |
6.7 |
– |
– |
6.7 |
||||||
|
Impairment losses |
– |
– |
– |
– |
0.2 |
– |
– |
0.2 |
||||||
|
Reversals of impairment losses |
– |
– |
– |
– |
– |
– |
– |
– |
||||||
|
EBITDA |
23.1 |
34.0 |
– |
57.1 |
57.9 |
75.1 |
– |
133.0 |
||||||
|
One-time items |
1.1 |
– |
– |
1.1 |
–0.1 |
– |
– |
–0.1 |
||||||
|
EBITDA pre one-time items (Segment result) |
24.2 |
34.0 |
– |
58.2 |
57.8 |
75.1 |
– |
132.9 |
||||||
|
|
|
|
|
|
|
|
|
|
||||||
|
EBITDA margin pre one-time items (% of sales) |
18.4 |
|
|
28.9 |
15.9 |
|
|
23.7 |
||||||
|
|
|
|
|
|
|
|
|
|
||||||
|
Net operating assets2 |
|
|
|
|
258.2 |
77.3 |
– |
335.5 |
||||||
|
Segment liabilities2 |
|
|
|
|
–74.5 |
– |
– |
–74.5 |
||||||
|
Investments in property, plant and equipment3 |
0.7 |
– |
– |
0.7 |
1.9 |
– |
– |
1.9 |
||||||
|
Investments in intangible assets3 |
0.1 |
– |
– |
0.1 |
0.3 |
– |
– |
0.3 |
||||||
|
|
|
|
|
|
|
|
|
|
||||||
|
Net cash flows from operating activities3 |
18.6 |
21.2 |
– |
39.8 |
29.9 |
57.9 |
– |
87.8 |
||||||
|
Business free cash flow |
12.3 |
24.6 |
– |
36.9 |
44.4 |
64.3 |
– |
108.7 |
||||||